Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

42.9%

3 terminated/withdrawn out of 7 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

N/A
4(80.0%)
Phase 3
1(20.0%)
5Total
N/A(4)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT04743245Not ApplicableTerminated

Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard.

Role: lead

NCT01630707Not ApplicableCompleted

Evaluation of the Delivery of Optimized Supersaturated Oxygen Therapy to Treat Patients With an Acute Heart Attack

Role: lead

NCT06438315Recruiting

SuperSaturated Oxygen Comprehensive Observational Registry

Role: lead

NCT05156996Terminated

A Prospective Real-World Multi-Center Post-Market Observational Evaluation of Supersaturated O2 Therapy Using the TherOx® Downstream® System

Role: lead

NCT04876040Not ApplicableWithdrawn

Incorporating Supersaturated Oxygen in Shock

Role: lead

NCT02603835Not ApplicableCompleted

Evaluation of Intracoronary Hyperoxemic Oxygen Therapy in Anterior Acute Myocardial Infarction Patients (IC-HOT)

Role: lead

NCT00175058Phase 3Completed

Acute Myocardial Infarction With HyperOxemic Therapy II (AMIHOT II)

Role: lead

All 7 trials loaded